InflaRx N.V. develops anti-inflammatory therapeutics that target the complement system through proprietary anti-C5a and anti-C5aR technologies. Its lead program, izicopan, is an orally administered small-molecule inhibitor of C5a-induced signaling via the C5a receptor, and vilobelimab is an intravenously delivered anti-C5a monoclonal antibody that selectively binds free C5a.
Company news commonly covers izicopan clinical-development strategy, preclinical pharmacology data, complement-mediated inflammatory disease programs, financial results, ordinary-share financings, Nasdaq listing compliance, annual meeting matters and investor communications. Updates also address the company’s operating group, which includes wholly owned subsidiaries in Germany and the United States.
InflaRx (Nasdaq: IFRX) reported preclinical in vitro data showing low reactive metabolite formation for izicopan in human liver microsomes versus higher levels for avacopan. Differences exceeded 100-fold at 5–10 minutes and were ~10-fold at 20–40 minutes. InflaRx noted izicopan did not inhibit CYP3A4 in vitro and cited prior Phase 1 and Phase 2a safety and PK/PD data, including ≥90% blockade of C5a-induced neutrophil activation.
InflaRx cautioned that in vitro findings do not directly predict clinical outcomes but said the results support izicopan’s differentiated preclinical profile within the C5aR1 inhibitor class.
InflaRx (Nasdaq: IFRX) will release its first quarter 2026 financial and operating results on May 7, 2026 before the market opens. No conference call is planned. The company develops anti-inflammatory therapeutics including oral izicopan and intravenous vilobelimab, and has operations in Germany and the U.S.
InflaRx (Nasdaq: IFRX) reported it has regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1). The closing bid price was at least $1.00 for 10 consecutive business days from April 13, 2026 to April 24, 2026, and Nasdaq closed the matter.
The company reiterated its lead programs, izicopan and vilobelimab, and listed investor contacts and subsidiaries.
InflaRx (Nasdaq: IFRX) reported mechanistic in vitro data showing izicopan does not exhibit time-dependent inhibition of CYP3A4 up to 100 µM, supporting a low risk of clinically relevant drug–drug interactions (DDIs) and liver toxicity. The Ki/Kinact study used midazolam and testosterone probes and confirmed prior marginal IC₅₀ findings.
Company data also note favorable PK/PD (≥90% C5a blockade over 14 days), tolerability in single doses 3–240 mg and multiple doses up to 90 mg twice daily, and supportive Phase 2a efficacy signals in hidradenitis suppurativa and chronic spontaneous urticaria.
InflaRx (Nasdaq: IFRX) will participate in the Raymond James 2026 Biotech Innovation Symposium in New York on April 14, 2026. The company will hold one-on-one investor meetings and present its pipeline highlights, including izicopan and vilobelimab, and corporate overview.
Contact details for investor relations and media are provided.
InflaRx (Nasdaq: IFRX) presented Phase 3 vilobelimab data for pyoderma gangrenosum at the 2026 AAD Annual Meeting (March 27-31, 2026). The trial enrolled 54 patients and was stopped early for futility. Results showed higher complete remission and ulcer-closure rates, strong C5a suppression (-76.6% vs -13.5%), and a generally favorable safety profile.
The company plans FDA discussions on a PG development path and expects future PG work likely with a partner.
InflaRx (Nasdaq: IFRX) reported full‑year 2025 results and highlighted positive Phase 2a data for oral C5aR inhibitor izicopan, prioritizing hidradenitis suppurativa (HS) and discussing Phase 2b design with the FDA. Cash and marketable securities totaled €46.2 million, funding operations to mid‑2027.
Company plans a China PK bridging study, ongoing collaborator discussions, and a virtual Capital Markets Day this spring.
InflaRx (Nasdaq: IFRX) announced a late-breaking oral presentation of Phase 3 vilobelimab results in pyoderma gangrenosum at the 2026 American Academy of Dermatology Annual Meeting in Denver, March 27-31, 2026.
The oral session is scheduled for March 28, 2026, 2:24-2:36 PM MT, presenter Benjamin Kaffenberger, MD. The company also highlights its izicopan program and anti-C5a/C5aR platform.
InflaRx (Nasdaq: IFRX) will report fourth quarter and full year 2025 results on March 19, 2026 before the market opens; no conference call is planned.
The company is developing izicopan (INF904), an oral C5aR inhibitor, and vilobelimab, an IV anti-C5a antibody, and maintains offices in Jena, Munich and Ann Arbor.
InflaRx (Nasdaq: IFRX) will participate in the Leerink Partners Global Healthcare Conference in Miami, March 8-11, 2026, with a fireside chat on March 9 at 9:20 AM ET and one-on-one investor meetings the same day.
Live streaming and replay of the fireside chat will be available via a company link; investor relations contacts are provided for meeting requests.